



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/577,866

10/03/2006

Alexander A. Khromykh

252007

2237

23460

7590

12/23/2008

LEYDIG VOIT & MAYER, LTD  
TWO PRUDENTIAL PLAZA, SUITE 4900  
180 NORTH STETSON AVENUE  
CHICAGO, IL 60601-6731

EXAMINER

BOESEN, AGNIESZKA

ART UNIT

PAPER NUMBER

1648

MAIL DATE

DELIVERY MODE

12/23/2008

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/577,866	<b>Applicant(s)</b> KHROMYKH ET AL.	
	<b>Examiner</b> AGNIESZKA BOESEN	<b>Art Unit</b> 1648	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 15 September 2008.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-37 is/are pending in the application.
- 4a) Of the above claim(s) 1-16 and 30-37 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 17-29 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                       | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | Paper No(s)/Mail Date. _____                                      |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>11/7/2008</u> .   | 6) <input type="checkbox"/> Other: _____                          |

### DETAILED ACTION

The Amendments filed September 15, 2008 and November 10, 2008 in response to the Office Action of May 14, 2008 are acknowledged and has been entered. Claim 17 was amended. Claims 17-29 are under examination in the present Office Action.

#### *Claim Rejections - 35 USC § 112*

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Rejection of claims 17-23 and 26-29 under 35 U.S.C. 112, first paragraph, **is maintained.**

Applicant's arguments have been fully considered but fail to persuade. Applicant amended the claims to recite attenuated Kunjin virus. As discussed in the rejection of record Applicant's claims are enabled for the following embodiments: There are two different suggestions for how Applicant could amend the claims to overcome the present enablement rejection.

1) "A method of **immunizing an animal** including the step of administering an isolated nucleic acid capable of producing an infectious attenuated Kunjin virus to said animal to thereby elicit a **protective immune response to a West Nile virus.**"

Or

2) "A method of **inducing an immune response** in an animal including the step of administering an isolated nucleic acid capable of producing an infectious attenuated Kunjin virus to said animal to thereby elicit an **immune response to at least another flavivirus.**"

Thus, if Applicant would like to recite the phrase “immunizing an animal” and “protective immune response” Applicant should limit the claims to recite the enabled embodiment of a West Nile virus, as discussed on the record. If Applicant would like to broadly recite "at least another flavivirus", Applicant should amend the claims to change the claim preamble to recite "A method of inducing an immune response" instead of "immunizing" which indicates vaccination, as discussed on the record.

Applicants amendment does not overcome the enablement rejection for essentially the same reasons as discussed on the record in the Office action of May 14, 2008. The recitation of “at least another flavivirus” encompassed a broad genus of viruses for which protective immunization does not currently exist. For example, there is no effective vaccine against hepatitis C virus which belongs to flavivirus family. While cross-protection between some flaviviruses exists, as argued by Applicants, it would have been highly unpredictable to conclude that immunization with infectious attenuated Kunjin virus would confer protection against infection with hepatitis C virus. Applicants have shown that the immunization with infectious attenuated Kunjin virus induces protection against West Nile virus. The skilled artisan would be required to conduct an undue amount of experimentation in order to determine whether immunization with infectious attenuated Kunjin virus would induce protection against other viruses encompassed by the genus of flaviviruses. Applicant’s amendment does not overcome the enablement rejection because the claims broadly recite the non-enabled embodiments as discussed above and for this reason the rejection is maintained.

*Biological Deposit Requirement*

Rejection of claim 25 under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement **is withdrawn** in view of Applicants explanation with regard to the availability of the NY99 strain. It is noted that present specification contains the information with regard to where the NY99 can be obtained.

***Claim Rejections - 35 USC § 102***

Rejection of claims 17-29 under 35 U.S.C. 102(a) as being anticipated by Hall et al. (PNAS, September 2, 2003, Vol. 100, p. 10460-10464 in IDS of 10/03/2006) **is withdrawn** in view of Applicants Declaration under 37 CFR § 1.132 filed September 15, 2008. Applicants state that the coauthors Nisbet, Pham, Pyke and Smith made no contribution to the subject matter currently claimed.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Rejection of claims 17-23, 26, and 28 under 35 U.S.C. 102(e) as being anticipated by Westaway et al. (US Patent 6,893,866) **is maintained.**

Applicant's arguments have been fully considered but fail to persuade. Applicants argue that '866 patent describes Kunjin replicon constructs that require the expression of flaviviral structural core prM and E proteins from Semliki Forest Virus for assembly of virus like particles

Art Unit: 1648

while the Kunjin virus of the present invention has the ability to produce a full length Kunjin virus genome that can be packaged into virions and can spread through multiple rounds of infection.

In response, the Office acknowledges that some of the Kunjin virus replicons disclosed in '866 patent comprise proteins from Semliki Forest virus which are required for assembly of the Kunjin replicon into a virus like particle. However the '866 patent discloses other embodiments where the Kunjin virus expresses its own proteins that are sufficient for packaging and replication of infectious Kunjin virus like particles (see claim 1 under b)).

'866 patent does not expressly disclose that the Kunjin virus like particles are attenuated, however, it discloses that the Kunjin virus like particles are "pseudo" infectious (see Example 3). The virus "attenuation" by definition means decreased virulence (ability to cause disease) while maintained ability to infect and replicate in the cells. It is the position of the Examiner that the Kunjin virus **like** particles disclosed by Westaway are attenuated because they are infectious (have the capability to replicate) without causing a disease.

Thus because Westaway discloses methods of generating immune responses comprising administering infectious Kunjin virus like particles, the rejection is maintained.

### ***Claim Rejections - 35 USC § 103***

Rejection of claims 17-24, 26-29 under 35 U.S.C. 103(a) as being unpatentable over Anraku et al. (Journal of Virology, April 2002, p. 3791-3799) **is withdrawn** in view of Applicant's arguments and amendments.

Art Unit: 1648

### ***Double Patenting***

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Rejection of claims 17-29 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 29-31 of copending Application No. 10/559,146 **is maintained**

Applicants state that Applicants will consider filing terminal disclaimer upon an indication that the rejection is no longer provisional.

### ***Conclusion***

No claim is allowed.

**THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Art Unit: 1648

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to AGNIESZKA BOESEN whose telephone number is (571)272-8035. The examiner can normally be reached on Monday through Friday from 9:00 AM to 5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.



Art Unit: 1648

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Agnieszka Boesen/

Examiner, Art Unit 1648

/Bruce Campell/

Supervisory Patent Examiner, Art Unit 1648